Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials

  |  Issue: October 2018  |  

Additional secondary endpoints will be measured out to Week 52, including knee stiffness and function, change in knee pain, quality of life measures and patient global impression of change for the treated knee OA.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Pain Therapeutics Inc. News release: Complete response letter issued for Remoxy. 2018 Aug 6.
  2. Pain Therapeutics Inc. News release: Pain Therapeutics announces results of FDA advisory committee meeting for Remoxy ER. 2018 Jun 26.
  3. Pain Therapeutics Inc. News release: Complete response letter for Remoxy. 2016 Sept 26.
  4. Centrexion Therapeutics Corp. News release: Centrexion Therapeutics announces first patient dosed in phase 3 trial of CNTX-4975 for the treatment of moderate to severe knee osteoarthritis pain. 2018 Feb 21.

Related Articles

    Centrexion’s Chili-Based Painkiller Offers Relief for 6 Months—Study

    (Reuters)—A synthetic version of a medicine traditionally extracted from chili plant relieved knee pain among osteoarthritis patients for up to six months, data showed, bringing Centrexion Therapeutics a step closer to developing a safe and effective analgesic. The drug, designed to be injected at the site of pain, is being developed by the privately-held company…

    Exercise Therapy Recommended to Manage Knee Osteoarthritis

    The benefits of exercise therapy for individuals with knee osteoarthritis (OA) are well known. The ACR strongly recommends both aquatic exercise and land-based aerobic and resistance exercise for managing knee OA.1 A recent Cochrane systematic review and meta-analysis concluded that high-quality evidence supports the use of exercise to reduce pain and improve physical function and…

    FDA to Review Abuse-Deterrent Oxycodone Capsule

    FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting….